Program
Vinblastine
Also written as “vinblastine sulfate”.
Its studies are mostly in Hodgkin Disease · Carcinoma, Renal Cell, led by 3 companies.
Furthest: phase 4, since Feb 14, 20254 company-led studies, 2 open or runningNext primary completion: Mar 31, 2028 (phase 4)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Takeda | 22 open or running | phase 4since Feb 14, 2025 | Nov 11, 2016 | Mar 31, 2028phase 4 · NCT06831370 |
| Hoffmann-La Roche | 10 open or running | phase 2since Aug 23, 2007 | Aug 23, 2007 | none ahead |
| Hope Cancer Institute | 10 open or running | phase 2since Nov 1, 1999 | Nov 1, 1999 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 1, 1999First study: phase 2 study in Kidney NeoplasmsNew to Hope Cancer InstituteHope Cancer Institute · NCT00003181 · 35 enrolled · United States
- Aug 23, 2007Hoffmann-La Roche's first study: phase 2 study in Carcinoma, Renal CellNew to Hoffmann-La RocheHoffmann-La Roche · NCT00520403 · 25 enrolled · Germany
- Nov 11, 2016Takeda's first study: phase 2 study in Hodgkin DiseaseNew to TakedaTakeda · NCT02979522 · 59 enrolled · United States, Brazil, Italy and more
- Feb 14, 2025Phase 4 study in Hodgkin DiseaseTakeda · NCT06831370 · 124 planned · India
Ahead
- Mar 31, 2028Primary completion: phase 4 study in Hodgkin DiseaseTakeda · NCT06831370
TargetBeta
TUBA1A →TUBA1B →TUBA1C →TUBA3C →TUBA3E →TUBA4A →TUBB →TUBB1 →TUBB2A →TUBB2B →TUBB3 →TUBB4A →TUBB4B →TUBB6 →TUBB8 →read by rule
“Tubulin inhibitor”ChEMBL 37, by rule
Other programs on the same 15 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Paclitaxelrule | Hoffmann-La Roche | phase 4 | 202 |
| Docetaxelrule | Sanofi | phase 4 | 199 |
| cabazitaxelrule | Sanofi | phase 4 | 21 |
| desoxyepothilone Brule | beijing-biostar-pharmaceuticals-co-ltd | phase 3 | 19 |
| plinabulinrule | beyondspring-pharmaceuticals-inc | phase 3 | 8 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06831370Hodgkin Disease · India | 4 | Recruiting | Takeda | Mar 31, 2028 | 124 |
| NCT02979522Hodgkin Disease · United States, Brazil, Italy and more | 2 | Active, not recruiting | Takeda | May 5, 2020 | 59 |
| NCT00520403Carcinoma, Renal Cell · Germany | 2 | Completed | Hoffmann-La Roche | Mar 2010 | 25 |
| NCT00003181Kidney Neoplasms · United States | 2 | UNKNOWN | Hope Cancer Institute | 35 |
How it is read
Names in the registry
- “Vinblastine”, 3 entries
- “vinblastine sulfate”, 1 entry
Conditions, from the studies’ own filings
- Hodgkin Disease, 2 studies
- Carcinoma, Renal Cell, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.